Metis Global Partners LLC Acquires 169 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Metis Global Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,513 shares of the biopharmaceutical company’s stock after acquiring an additional 169 shares during the period. Metis Global Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $3,927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Focus Financial Network Inc. grew its holdings in Regeneron Pharmaceuticals by 7.4% during the 3rd quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 37 shares in the last quarter. Americana Partners LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $330,000. Farther Finance Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 7.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock worth $761,000 after acquiring an additional 53 shares in the last quarter. Empire Life Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $5,030,000. Finally, Van ECK Associates Corp lifted its position in shares of Regeneron Pharmaceuticals by 8.9% during the third quarter. Van ECK Associates Corp now owns 58,136 shares of the biopharmaceutical company’s stock valued at $61,115,000 after buying an additional 4,742 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $698.74 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.39 billion, a PE ratio of 18.25, a P/E/G ratio of 2.34 and a beta of 0.08. The firm has a 50 day moving average of $698.51 and a two-hundred day moving average of $868.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.